Core Insights - The FDA has approved Novo Nordisk's new higher dose of Wegovy® HD (semaglutide) injection 7.2 mg, which has shown significant weight loss in adults with obesity, particularly in the STEP UP trial [1][2] - Wegovy® HD is positioned as a superior weight loss medication compared to other GLP-1 medications, with additional cardiovascular benefits for patients with known heart disease [1][2] Summary by Sections FDA Approval and Clinical Profile - The approval of Wegovy® HD is based on the STEP UP trial, which demonstrated an average weight reduction of approximately 21% at 72 weeks for those who remained on treatment [1][2] - The previous highest approved dose was 2.4 mg, which also aimed to reduce the risk of major cardiovascular events in adults with obesity or overweight [1][2] STEP UP Trial Results - In the STEP UP trial, about one in three participants taking Wegovy® HD achieved a weight loss of 25% or more [2] - The average weight loss for Wegovy® HD was around 21% if all patients stayed on treatment, compared to 18% for the 2.4 mg dose [2][3] - The trial included 1,407 adults with a BMI of 30 kg/m² or greater, without diabetes, and lasted for 72 weeks [6] Adverse Reactions - Common adverse reactions reported with Wegovy® HD included nausea, vomiting, dysesthesia, and abdominal pain, with dysesthesia occurring at a higher rate compared to the 2.4 mg dose and placebo [4][6] - The incidence of altered skin sensations was notably higher in the Wegovy® HD group (22%) compared to the 2.4 mg group (6%) and placebo (0.3%) [4][6] Availability and Access - Wegovy® HD is set to be available in April 2026 through over 70,000 pharmacies in the US, including major chains like CVS and Costco, as well as select telehealth providers [4] - Novo Nordisk will provide information on coverage and savings options for eligible patients to help reduce out-of-pocket costs [4] Company Background - Novo Nordisk has over 100 years of experience in developing innovative medicines for chronic diseases, including diabetes and obesity [15] - The company emphasizes a long-term focus on responsible business practices and aims to improve health outcomes for patients with obesity [15]

Core Viewpoint - Zealand Pharma strengthens its leadership in innovation for obesity and related conditions with the appointment of Steven Johnson as Chief Development Officer [2][4] Company Overview - Zealand Pharma A/S is a biotechnology company focused on the discovery and development of innovative peptide-based medicines, with more than 10 drug candidates in clinical development, including two that have reached the market and three in late-stage development [5][6] Leadership Appointment - Steven Johnson brings nearly 30 years of experience in drug development and regulatory strategy, previously serving at UCB Biopharma and holding senior roles at Medpace, Inc. and Novo Nordisk [3][4] - His role will involve leading regulatory and development strategies, enhancing the company's R&D leadership alongside CMO David Kendall and CSO Utpal Singh [4][7] Strategic Focus - The appointment comes as Zealand Pharma collaborates with Roche to co-develop and co-commercialize petrelintide, aimed at addressing obesity and related complications [4][7] - The leadership team aims to align human-centered innovation with world-class science to develop new therapies that could redefine the standard of care for obesity [4]

Core Insights - Eli Lilly's Zepbound (tirzepatide) demonstrated superior efficacy in weight loss compared to Wegovy (semaglutide) in the SURMOUNT-5 trial, achieving an average weight loss of 20.2% versus 13.7% at 72 weeks [1][2][3] Group 1: Trial Results - Zepbound participants lost an average of 50.3 lbs (22.8 kg), while Wegovy participants lost an average of 33.1 lbs (15.0 kg), indicating a 47% greater relative weight loss with Zepbound [2] - In key secondary endpoints, 64.6% of Zepbound participants achieved at least 15% weight loss compared to 40.1% for Wegovy [2][5] - Zepbound also showed a greater average waist circumference reduction of 7.2 inches (18.4 cm) compared to 5.1 inches (13.0 cm) for Wegovy [2][5] Group 2: Safety and Tolerability - The safety profile of Zepbound was consistent with previous trials, with gastrointestinal-related adverse events being the most common and generally mild to moderate [5] - 6.1% of Zepbound participants discontinued treatment due to adverse events, compared to 8.0% for Wegovy [5] Group 3: Product Information - Tirzepatide is marketed as Zepbound in the U.S. for adults with obesity or overweight with weight-related medical problems, and as Mounjaro for type 2 diabetes [6][10] - Zepbound is FDA-approved for adults with moderate-to-severe obstructive sleep apnea and obesity [10]